Acumen Pharmaceuticals, Inc.
ABOS
$0.988
-$0.092-8.52%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 91.18M | 902.00K | 19.53M | 12.45M | 40.95M |
| Gross Profit | -91.18M | -902.00K | -19.53M | -12.45M | -40.95M |
| SG&A Expenses | 5.03M | 5.02M | 4.85M | 5.33M | 5.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.60M | 32.27M | 24.38M | 17.77M | 18.49M |
| Operating Income | -39.60M | -32.27M | -24.38M | -17.77M | -18.49M |
| Income Before Tax | -37.15M | -29.77M | -20.54M | -14.87M | -16.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.15M | -29.77M | -20.54M | -14.87M | -16.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.15M | -29.77M | -20.54M | -14.87M | -16.50M |
| EBIT | -39.60M | -32.27M | -24.38M | -17.77M | -18.49M |
| EBITDA | -39.58M | -32.25M | -24.36M | -17.76M | -18.47M |
| EPS Basic | -0.62 | -0.50 | -0.34 | -0.25 | -0.28 |
| Normalized Basic EPS | -0.39 | -0.31 | -0.21 | -0.16 | -0.18 |
| EPS Diluted | -0.62 | -0.50 | -0.34 | -0.25 | -0.28 |
| Normalized Diluted EPS | -0.39 | -0.31 | -0.21 | -0.16 | -0.18 |
| Average Basic Shares Outstanding | 60.08M | 60.08M | 60.08M | 59.81M | 58.01M |
| Average Diluted Shares Outstanding | 60.08M | 60.08M | 60.08M | 59.81M | 58.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
